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Abstract: This preliminary study investigated the use of poly (2-hydroxyethyl   methacrylate) 
(pHEMA) nanoparticles for the delivery of the deoxyribonucleic acid (DNA) vaccine pCAG-
HAk, which expresses the full length hemagglutinin (HA) gene of the avian influenza A/Eurasian 
coot/Western Australian/2727/1979 (H6N2) virus with a Kozak sequence which is in the form 
of a pCAGGS vector. The loaded and unloaded nanoparticles were characterized using field-
emission scanning electron microscopy. Further characterizations of the nanoparticles were 
made using atomic force microscopy and dynamic light scattering, which was used to investi-
gate particle size distributions. This preliminary study suggests that using 100 µg of pHEMA 
nanoparticles as a nanocarrier/adjuvant produced a reduction in virus shedding and improved 
the immune response to the DNA vaccine pCAG-HAk.
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Introduction
Nanotechnology has been able to deliver a wide range of new and novel materials. 
These new nanomaterials are increasingly becoming the subject of many investiga-
tions in several fields, particularly those of engineering, biotechnology, and biomedi-
cal sciences.1,2 Nanomaterials can be made from a wide range of solid materials such 
as metals, ceramics, polymers, organic materials, and composites. They can come in 
a wide range of morphologies; namely, spheres, rods, tubes, and plates. The use of 
nanoparticles of biodegradable polymers is being extensively studied since they pro-
vide an attractive alternative for a number of nanomedical applications by providing 
a delivery platform for the sustained, controlled, and targeted release of drugs and 
immunogens. These immunogens, therapeutic drug agents, or in some cases imaging 
agents can be loaded into a biodegradable polymer matrix. Once the polymer is admin-
istered, the nanoparticles of the matrix slowly begin to degrade and release the drug or 
immunogen agents. In addition, the biodegradable nanoparticles can be administered 
through several different delivery routes, such as oral, nasal, ocular, transdermal, and 
intravenous routes.3 Ideally these nanoparticles should be inert, biocompatible, and 
biodegradable. They also need to be stable in vivo, easily attached to immunogens, 
effectively delivered, and have little or no side effects.4–6
The 1918 Spanish flu is considered to be the deadliest disaster in human history. 
The flu killed more than 50 million people worldwide and was related to an avian flu 
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virus H1N1.7 In the late 1990s, the re-emergence of avian 
influenza demonstrated that this type of virus is persistent and 
can reach endemic levels in many south-east Asian countries 
if not effectively managed. Influenza still remains an impor-
tant and threatening disease to both humans and animals. In 
contrast to measles, smallpox, and poliomyelitis, influenza 
is caused by viruses that undergo a continuous antigenic 
modification within their natural host. The natural reservoir 
for these viruses is aquatic, migratory birds, which usually 
flock in large numbers and travel great distances between 
countries. When these birds associate with the local terrestrial 
poultry they can occasionally transmit transitory infections. 
The diversity of diseases that can be transmitted range from 
mild respiratory illnesses to fatal systematic diseases. The 
development of new antiviral drugs and vaccines based on 
nanoparticles has the potential to provide an effective method 
in dealing with any possible future outbreaks of the influenza 
virus strains.
Polymer based nanoparticles have been found to improve 
the therapeutic efficacy and reduce the potential side effects 
of many therapeutic drug agents. The major challenge fac-
ing nanomedicine today in using these polymeric delivery 
systems is to engineer and manufacture a biodegradable 
nanoparticle matrix with the desired physiochemical and 
pharmaceutical properties. If these optimum properties 
are achieved, then delivering the payload should permit 
the controlled release of medication concentration within 
the effective therapeutic window and dosage.3 The poly-
meric nanoparticle matrix used in any particular application 
is an important factor because it can influence parameters 
such as protein loading,   stability, biodegradability, and 
  bioavailability.8 Thus there are a number of commercially 
available biodegradable polymers currently used in poly-
meric nanoparticle matrix formulations. For example, the 
most widely researched Food and Drug Administration 
(FDA)-approved biodegradable polymers in the literature 
are poly (lactide) (PLA), poly (D,L-lactide-co-glycolide) 
(PLGA) (a copolymer of PLA and poly (glycolide) [PGA]), 
and poly (ε-caprolactone) (PCL).9
The polymers PLA, PLGA, PGA, and PCL were all 
originally synthesized in the 1950s for nondrug delivery 
functions such as surgical sutures, textile grafts, and implants. 
Since this time, these polymers have been also investigated 
for a variety of drug agent delivery platforms in a number 
of therapeutic applications. Unfortunately, there are a num-
ber of disadvantages in using these polymers; for example, 
their strong mechanical strength and slow degradation rates, 
which can lead to a slow drug release that does not provide 
the desired concentration. In addition, the bioactivity of 
proteins and peptides encapsulated in the polymer matrix 
can deteriorate since the polymers’ hydrophobic nature can 
produce an acidic microenvironment. This microenviron-
ment results from water being unable to enter the matrix 
and the accumulation of acidic breakdown products (lactic 
and glycolic acid end groups). There are also issues with the 
hydrophobic nature of the polymeric nanoparticles interact-
ing with hydrophilic molecular probes used for targeting, 
which can lead to complications in the drug preparation 
technology.8 It is due to these disadvantages that many 
researchers look for other novel biodegradable polymers 
and copolymer delivery platform systems for immunogens 
and therapeutic drugs.
Many synthetic methods have been used to manufacture 
a variety of nanopolymeric particles with various sizes and 
morphologies. The latter parameters having a dominant bear-
ing on the final properties of the nanomaterial synthesized. 
Some of the attractive features of using a synthetic sono-
chemical approach are: less complications, reduced process-
ing time, generally more efficient, and economical.10–13 The 
sonochemical technique is based on the acoustic cavitation 
phenomenon, which produces the continuous formation, 
growth, and final implosive collapse of bubbles in the solu-
tion being sonicated. This creates numerous hot-spots in the 
solution, which provide sufficient energy for the formation 
and growth of nanoparticles. This synthetic process can be 
extended to polymers and composite materials.14,15
In this article, the development of biocompatible and 
biodegradable nanosized poly (2-hydroxyethyl methacrylate) 
(pHEMA) particles that are used as deoxyribonucleic acid 
(DNA) vaccine carriers is described. DNA vaccination is 
an effective procedure for inducing protective immunity 
against a number of infectious and noninfectious diseases in 
a variety of animals.16 However, several factors can influence 
their performance; for example, the delivery technique will 
dictate the DNA dosage level that is required to solicit an 
effective immune response. In addition, the rapid degrada-
tion and low cellular uptake of plasmid DNA can also have a 
dramatic effect on the efficiency of the exposed plasmid DNA 
vaccines.17 To remediate these problems, plasmid DNA vac-
cines have been combined with particles, via adsorption, or 
encapsulation, or by co-formulation to stabilize the plasmid 
DNA delivery. Combining plasmid DNA with particles sig-
nificantly reduces the degradation process and also stabilizes 
the vaccine. It also has the advantage of providing particular 
materials that are effectively taken up by the antigen present-
ing cells, thus providing an adjuvant (synergistic) effect. 
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Historically, adjuvants have been successfully used in the 
development of vaccines.18 Conventional chemical adju-
vants such as bupivacaine19 or Marcaine® (Hospira, Inc, 
Lake Forest, IL), ubenimex,20 monophosphoryl lipid A,21 
QS-21 saponin,22 and levamisole23 have been investigated 
successfully. These adjuvants were able to facilitate a positive 
immune response to the DNA vaccines being tested.
The discovery in 1995 of injecting solid inert beads with 
DNA-encoded antigens resulted in the priming of CD8T cells 
for a direct immune response.24 Since then, inert nanopar-
ticles have also been able to induce strong immune responses 
to protein and peptide antigens in mice,25,26 sheep,18 pigs,27 
and cattle.27 In addition, both metals and inorganic nanoma-
terials have been used in similar biomedical applications. 
For example, a metal such as gold which is nontoxic, inert, 
and stable within the body environment has been used as a 
contrast agent in cancer diagnosis and photodermal   cancer 
therapy. It has also been effectively used as a delivery 
platform for oligonucleotide, insulin, and genes.28 Metal 
oxide NPs such as magnetite (Fe3O4) have been used as 
magnetically targeted drug delivery platforms due to their 
biodegradability and biocompatibility. Once these NPs 
are introduced into the blood stream, the particles flow to 
the specific location of interest in the body where a strong 
magnetic field can be used to pull them out of suspension 
and deliver the pharmaceutical payload.29 Furthermore, an 
inorganic material such as mesoporous silica, with its con-
trollable structural properties and biocompatibility, has been 
effectively used to deliver calcein.30
In the case of DNA vaccines, cationic nanoparticles 
have been formulated with plasmid DNA encoding of a 
reporter gene. This vaccine was able to enhance the   in-vitro 
cell transfection efficiency and achieve a substantial cellular 
immune response (16–200 times greater than the normal 
plasmid DNA by itself) in mice cells via a number of delivery 
routes.4,31–33 Furthermore, it has also been shown that when 
both the cholera toxin and lipid A were administered with a 
  nanoparticle-based plasmid DNA, there was an overall syner-
gistic effect which enhanced the immune response of the cel-
lular tissues.5,33 Thus, nanoparticles can also be seen as a novel 
class of adjuvants, with the potential to be effective delivery 
platforms for proteins and plasmid DNA immunogens, 
which can successfully induce a positive immune response. 
In   addition, the nanoparticle delivery platform distributes its 
payload without the usual side effects associated with local 
tissue damage caused by conventional chemical adjuvants.
In the past, polymeric particles, both synthetic and natural, 
have been investigated as potential carriers for the delivery of 
plasmid DNA to provide cellular immunity. These particles 
have been found to provide suitable accommodation to plas-
mids of varying sizes and to provide protection to the plasmid 
DNA payload from the in-vivo effects of extracellular degrada-
tion. In addition, these particles have also provided an enhanced 
response from the immune system. The first polymeric particle 
delivery system used for delivering DNA used microsized 
particles of poly   (lactideco-glycolide).34 Recently, polymeric 
nanoparticles have been investigated for possible plasmid 
DNA vaccine carriers. The most attractive features of using 
nanosized polymeric delivery systems are: the nanostructure 
provides an effective scaffold which is capable of providing 
a controlled release of DNA, polymeric nanoparticles can 
easily be manufactured, and they are biocompatible and 
biodegradable.35,36 Recently, a polymeric microparticle study 
of formulated plasmid DNA encoding of the nucleoprotein 
gene A/PR/8/34 of the (H1N1) virus revealed an enhanced 
immune response in mice37 and a biodegradable pHEMA has 
also been used in a similar drug delivery system.38,39 However, 
to date there has been no reports of a nanoparticle pHEMA-
based avian influenza DNA vaccine for the H6N2 virus. The 
present study investigated the immunologic effect of a novel 
polymeric nanomaterial, pHEMA, as a potential plasmid DNA 
nanocarrier for a vaccine against the wild bird (H6N2) avian 
influenza virus. A major advantage of using pHEMA as the 
vaccine carrier is that this particular nontoxic copolymer has 
FDA approval for use in contact lenses, implant coatings, and 
prostheses.
Material and methods
Chemicals
All chemicals were purchased from Sigma-Aldrich (Castle 
Hill, NSW, Australia) and used without further purification. 
Milli-Q® water (18.3 MΩ cm−1) was used throughout all 
synthesis procedures involving aqueous solutions. The sur-
factant used in the preparation of the pHEMA nanoparticles 
was poly (vinyl alcohol) (PVA) and was prepared by dis-
solving 1 g of PVA in a 100 mL solution of Milli-Q® water. 
Throughout the preparation of the nanoparticles, a 1% w/v 
of PVA was used.
Formulation and optimization of solvent
The optimization of the solvent used for mixing pHEMA 
and DNA, and the calculation of DNA binding, was deter-
mined from a comparative study. The study looked at 
dissolving 1 g of pHEMA in various solutions where the 
percentage w/v of an alcohol (ethanol) in a Milli-Q water 
solution was adjusted. In the first case, a 100 mL solution 
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of pure Milli-Q water was used; the second solution con-
sisted of a mixture composed of 50 mL of Milli-Q water 
and 50 mL of ethanol; the third solution consisted of a 
mixture composed of 25 mL of Milli-Q water and 75 mL 
of ethanol; and the final solution consisted of 100 mL of 
ethanol. All polymer solvent solutions prepared contained 
1% w/v of pHEMA. During the preparation of all loaded 
and unloaded nanoparticle preparations, 2 mL of pHEMA 
(1% w/v) was used.
Preparation of pHEMA nanoparticles
The preparation of the unloaded pHEMA nanoparticles 
started by adding a 2 mL solution of pHEMA (1% w/v) to 
a 10 mL glass tube supported in an ice bath. The pHEMA 
was then exposed to ultrasonic irradiation for 30 seconds 
before 1 mL of PVA (1% w/v) was added to the glass tube 
dropwise and then sonicated for a further 10 minutes. The 
ultrasonic processor used throughout these procedures was 
a UP50H (50 W, 30 kHz, MS7 Sonotrode (7 mm   diameter, 
80 mm length)) supplied by Hielscher Ultrasound 
  Technology (see Figure 1A).
Preparation of plasmid DNA vaccine  
with pHEMA
The formulation of the pHEMA nanoparticles and the DNA 
composite begins with a 4 mL solution of pHEMA (1% w/v 
in 100% ethanol blend) being added to a 10 mL glass tube 
supported in an ice bath. The solution was then sonicated for 
30 seconds before a 2 mL solution (1% w/v) of PVA was 
added dropwise to the glass tube, which was then sonicated 
for a further 2 minutes. This was followed by the dropwise 
addition of 400 µL of plasmid DNA (9.3 µg/µL) to the glass 
tube and then sonicated for a further 10 minutes. At the end 
of this time, the solution was filtered three times through 
a 0.2 µm membrane to remove the surfactant. The filtered 
solution was then centrifuged at 15,000× g for 20 minutes at 
room temperature. The resultant pellet was then dissolved in 
phosphate buffered saline (PBS), and the amount of plasmid 
DNA coated nanoparticles was calculated by subtracting the 
amount of DNA in the supernatant from the total DNA added. 
The DNA concentration in the supernatant was measured by 
a nanodrop ND-1000 Spectrophotometer (Thermo Scientific, 
Waltham, MA).
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Figure 1 (A) Ultrasonic processor used in the synthesis of nanoparticles. (B–D) Dynamic light scattering data of unloaded and DNA-loaded pHEMA nanoparticles in three 
solvent mixtures.
Abbreviations: DNA, deoxyribonucleic acid; pHEMA, poly (2-hydroxyethyl methacrylate).
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Characterization of pHEMA 
nanoparticles
The structural and morphological features of the dispersed 
pHEMA nanoparticles were investigated using field-emission 
scanning electron microscopy (FESEM). Samples were 
dropped onto a conventional SEM stub and the latter coated 
with Au. All FESEM scans were taken using a high resolution 
Zeiss 1555 Variable Pressure Field Emission at 3 kV with a 
30 µm aperture under 1 × 10−10 Torr pressure. Atomic force 
microscopy (AFM) imaging of the pHEMA nanoparticles 
was carried out by first dropping a few drops of an ethanol 
solution containing the nanoparticles onto a freshly cleaved 
mica substrate and then allowing the solution to evaporate 
before imaging the dry substrate using a Pico-Plus AFM 
operating in Tapping Mode (molecular imaging). The probes 
used during the scanning mode were silicon tips with a spring 
constant of 42 N/m and a resonant frequency of 300 kHz. 
The dynamic light scattering (DLS) technique was used to 
investigate the pHEMA nanoparticle sizes. The loaded and 
unloaded pHEMA nanoparticles were dispersed in ethanol 
prior to being investigated by the DLS. The detector used was 
a Malvern Zetasizer 3000 HAS (Malvern Instruments, Ltd, 
Worcestershire, UK) (633 nm) operated at 25°C.
Antibody response in animal  
(chicken) model
For Australian biosecurity reasons, a low pathogenic avian 
influenza virus, A/Eurasian coot/Western Australia/2727/1979 
(H6N2), isolated from a healthy Eurasian coot (Fulica atra) in 
Australia, was selected to perform this DNA vaccine adjuvant 
study. The procedure of combining the pCAG-HAk plasmid 
DNA that expresses the complete hemagglutinin (HA) gene 
of the avian influenza virus (H6N2), together with a Kozak 
sequence, in a pCAGGS vector used in the DNA vaccine has 
been previously described by Shan et al.40
Vaccination regime
All bird experiments were carried out with the approval 
of Murdoch University’s animal ethics committee, and 
all experiments were conducted in accordance with the 
  Australian National Health and Medical Research Council’s 
(NHMRC) code of practice for the care and use of animals 
for scientific purposes. The birds selected for this study were 
3-week-old Hy-Line chickens that were free from the avian 
influenza. The chickens were accommodated in free-range 
pens with access to feed and water, and were maintained at 
the Animal Resource Centre, Murdoch University, Perth, 
Western Australia.
The experimental immunization protocol used in the 
bird vaccine study is presented in Table 1 and contains 
information regarding bird numbers and vaccine dosage. 
During the protocol, each bird received two intramuscular 
injections of 0.2 mL at 3-week intervals. The injection pro-
cedure involved a 0.1 mL dose being injected in each leg. 
Over this period, the six control birds received a 200 µL 
dose of PBS without adjuvant, five birds received a 100 µL 
dose of pCAG-HAk without adjuvant, and the remaining 
sets of birds received doses of 10 µL, 100 µL, and 200 µL 
of pCAG-HAk with pHEMA. Sera samples were collected 
weekly to detect and monitor the H6 specific antibody of 
hemagglutination-inhibition (HI).40,41 Three weeks after the 
booster vaccination, each bird received a 0.5 mL dose of the 
wild bird H6N2 avian influenza virus (106.5 EID50/0.1 mL) 
via three delivery routes. In the first route, the bird received 
0.1 mL of the H6N2 virus by nasal instillation, the second 
0.1 mL was introduced via eye drops, and the final 0.3 mL 
dose was delivered through an oral route. Following the virus 
challenge, a daily observation of all birds was undertaken and 
either oropharyngeal or cloacal swabs were collected every 
second day over a 7-day period. The virus isolation procedure 
was performed in accordance with the manual of diagnostic 
tests and vaccines for terrestrial animals.41
Results and discussion
Optimization of the solvent revealed that the pHEMA nano-
particles prepared with 100% ethanol produced the highest 
DNA binding rate. The total plasmid DNA used in each 
solvent experiment was 581.3 ng/µL, and the maximum 
DNA binding rate was found in 100% ethanol solution, with 
only 28.3 ng/µL of DNA remaining in the supernatant (see 
Table 2). Thereafter, 100% ethanol was used for the prepara-
tion of the pHEMA adjuvant vaccine for the rest of the study. 
In the 100% water case, the unloaded particles of pHEMA 
ranged in size from 168 to 314 nm, with the unloaded particles 
being larger in most cases. In the 50% ethanol and 50% water 
case, the pHEMA particles ranged in size from 185 to 311 nm, 
Table 1 Immunization protocol in chicken vaccine study
Group Vaccine Dose, μg Adjuvant Number  
of chickens
1 PBS 100 None 6
2 pCAG-HAk 100 None 5
3 pCAG-HAk 10 pHEMA 5
4 pCAG-HAk 100 pHEMA 3
5 pCAG-HAk 200 pHEMA 4
Abbreviations:  PBS,  phosphate  buffered  saline;  pHEMA,  poly  (2-hydroxyethyl 
methacrylate).
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Table 2 The effect of solvent composition on plasmid DNA 
binding to pHEMA
Solvent 100% Milli-Q®  
water
50% Milli-Q®  
water  
50% ethanol
100%  
ethanol
DNA concentration  
in supernatant, ng/µL
505.9 208.8 28.30
Bonded DNA, ng/µL 75.40 372.5 553.0
Bonded DNA, % 13.00 64.10 95.10
Abbreviations:  DNA,  deoxyribonucleic  acid;  pHEMA,  poly  (2-hydroxyethyl 
methacrylate).
Figure  2  Field-emission  scanning  electron  microscopy  images  of  the  unloaded 
and  DNA-loaded  pHEMA  nanoparticles  with  the  spherical  particle  morphology. 
(A) Unloaded pHEMA nanoparticles at low magnification (scale bar 1 µm) and (B) at 
high magnification (scale bar 200 nm); and (C) DNA-loaded pHEMA nanoparticles at 
low magnification (scale bar 1 µm) and (D) at high magnification (scale bar 200 nm).
Abbreviations:  DNA,  deoxyribonucleic  acid;  pHEMA,  poly  (2-hydroxyethyl 
methacrylate).
Figure 3 Atomic force microscopy profile images of the unloaded and DNA-loaded 
pHEMA nanoparticles with spherical particle morphology. (A) Unloaded pHEMA 
nanoparticles at low magnification and (B) at high magnification; and (C) DNA-loaded 
nanoparticles of pHEMA at low magnification and (D) at a higher magnification.
Abbreviations:  DNA,  deoxyribonucleic  acid;  pHEMA,  poly  (2-hydroxyethyl 
methacrylate).
Table 3 Antibody response prior to and post virus challenge
Time Naive  
control
pCAG-HAk
No pHEMA  
(adjuvant)
pHEMA, μg
Prior 0 0 10 100 200
Posta 6.0 ± 2.0 5.6 ± 1.7 6.6 ± 2.1 5.3 ± 1.5 5.3 ± 1.5
Note: aValues represent geometric mean titer (log2) ± standard deviation of each 
bird group.
Abbreviation: pHEMA, poly (2-hydroxyethyl methacrylate).
with the unloaded particles being larger in half of the   trials. 
While in the 100% ethanol case, the pHEMA particles 
ranged from 136 to 328 nm, with the unloaded particles being 
smaller in more than half of the trials (see Figure 1). Figure 2 
presents FESEM images of the unloaded and DNA-loaded 
pHEMA nanoparticles; the images reveal that the nanopar-
ticles range in size from 120 to 330 nm and have spherical 
morphology. This is confirmed by the AFM profile images of 
the unloaded and loaded pHEMA nanoparticles presented in 
Figure 3. The DLS, FESEM, and AFM analysis all confirm 
that the nanoparticles range in size from 120 to 330 nm; the 
morphology is spherical in the unloaded system and appears 
to be unchanged by the incorporation of the DNA.
Following DNA loading procedures, the efficiency of the 
nanovaccine was tested in a bird (Hy-Line chicken) model. 
Three weeks post second vaccination, no H6 HI antibody titer 
was detected in any of the Hy-Line chickens. At the end of 
10 days post virus challenge, all birds sero-converted with a 
range of HI titers, which are presented in Table 3. There was a 
significant difference (P , 0.05) in the geometric mean titer 
of the HI antibody prior to and post virus challenge using 
the paired-sample t-test.
Table 4 presents the level of virus shedding in both the 
oropharyngeal and cloacal swabs in vaccinated birds follow-
ing the H6N2 avian influenza virus challenge. Comparing the 
pCAG-HAk vaccinated group with the naive control group, 
we can see that the virus excretion rate in the oropharyngeal 
swabs of 70.8% in the naive group was reduced to 45% 
in the pCAG-HAk group following the virus challenge. 
While   cloacal swabs for the naive control group recorded a 
12.5% value, the pCAG-HAk vaccinated group was reduced 
to 0% value for the post virus challenge.
Table 4 reveals that there is a significant difference 
between the pCAG-HAk vaccinated group and the naive 
control group for both oropharyngeal and cloacal swabs. 
In comparison with the naive control group, the 100 µg 
pHEMA adjuvanted plasmid pCAG-HAk group has shown a 
significant decrease in virus shedding in both oropharyngeal 
and cloacal swabs. This result suggests that using pHEMA as 
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the efficiency of the particular delivery system.44 Recently, 
a variety of inert nanoparticles was investigated and found 
to be effective delivery vehicles for protein and peptide 
antigens.4,28–30,39,45,46 However, the application of nanoparticles 
as delivery platforms with DNA vaccines as payloads is only 
at the exploratory stage.33,43 In this present preliminary study, 
the potential application of using a biodegradable, nontoxic 
copolymer (pHEMA nanoparticles) as a delivery platform 
to carry pCAG-HAk plasmid DNA has been investigated. In 
the past, pHEMA has been used in drug delivery systems;26,31 
however, to date, it appears that this study is the first to use 
pHEMA nanoparticles as an adjuvant in DNA vaccination.
Conclusion
This preliminary study suggests that using pHEMA nanopar-
ticles as a nanocarrier/adjuvant have improved the immune 
response to the DNA vaccine pCAG-HAk. A reduction in 
virus shedding was detected in both oropharyngeal and 
cloacal swabs for the 100 µg pHEMA adjuvant DNA vaccine. 
Three pHEMA adjuvant doses (10, 100, and 200 µg) were 
  investigated. The study revealed that there was a dose response 
effect, with the 100 µg producing the most significant amount 
of virus shedding. The mechanism behind this adjuvant effect 
has not been resolved, but the reduction of virus shedding in 
the oropharynx of chickens challenged with the wild bird 
H6N2 influenza virus warrants further investigation.
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performance. In addition, the bonding mechanism appears to 
be complex because the optimum effect occurred in the bird 
group that received the 100 µg dose. Both the 10 and 200 µg 
dose groups were less effective. The mechanisms behind 
the observed adjuvant effect have not yet been resolved. 
Some possible mechanisms that could have affected the 
performance of the pHEMA nanoparticle delivery platform 
include: the surface distribution of the plasmid DNA on the 
nanoparticles, the delivery platform prevented effective DNA 
degradation, which in turn affected the targeting of the DNA 
to antigen presenting cells.34,42 Another factor that needs to 
be investigated further is the effect of the nanoparticle size 
used in the delivery platform. In this study, the pHEMA 
nanoparticle size ranged from 120 to 330 nm, and this size 
range could have influenced the delivery mechanism. Recent 
studies have shown that the size of the nanoparticles being 
used as the DNA delivery platforms can have a significant 
effect on the DNA vaccine efficacy.5,18,25,43
The use of particular delivery platforms as a novel method 
of delivering a payload of proteins and/or plasmid DNA immu-
nogens to induce a positive immune response is a research 
area that is currently receiving a great deal of interest. The 
characteristics of both micro- and nanosized particles can have 
a significant impact on the overall performance of the delivery 
system. For example, the size, shape, and surface properties 
such as hydrophobicity and surface charge directly affect 
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